BioPOA Corp., a South Korean veterinary bio-pharmaceutical company, announced that it has been selected for the “Innovation Premier 1000,” a flagship government-led program jointly organized by the Financial Services Commission (FSC) and key government ministries.
The Innovation Premier 1000 is a collaborative initiative designed to identify small-to-medium and mid-sized enterprises (SMEs) with high growth potential and advanced technological capabilities. The program provides comprehensive financial backing and growth support packages to help high-performing, innovative companies secure long-term market competitiveness and growth momentum.
BioPOA is a fully integrated veterinary pharmaceutical company equipped with an end-to-end "one-stop" platform covering the entire pipeline—from early-stage R&D to full-scale commercial manufacturing. Powered by its proprietary SAVE (Synthetic Attenuated Virus Engineering) reverse genetics technology, the company has established a strong technical edge in the global animal health sector.
Notably, BioPOA’s flagship PoaVac PRRS Live Vaccine has secured regulatory approvals not only in South Korea, but also in Thailand, Cambodia, and Mexico, driving consistent revenue growth. The company is actively accelerating its global footprint, with regulatory review and approval processes currently underway in key Southeast Asian markets, including Vietnam and the Philippines.
"Our selection for the Innovation Premier 1000 is a testament to our R&D capabilities and market growth potential," said Sunhee Cho, CEO of BioPOA. "With this government backing, we will continue investing in strengthening our core competencies to boost our global competitiveness and accelerate our expansion into international markets."
BioPOA Corp., a South Korean veterinary bio-pharmaceutical company, announced that it has been selected for the “Innovation Premier 1000,” a flagship government-led program jointly organized by the Financial Services Commission (FSC) and key government ministries.
The Innovation Premier 1000 is a collaborative initiative designed to identify small-to-medium and mid-sized enterprises (SMEs) with high growth potential and advanced technological capabilities. The program provides comprehensive financial backing and growth support packages to help high-performing, innovative companies secure long-term market competitiveness and growth momentum.
BioPOA is a fully integrated veterinary pharmaceutical company equipped with an end-to-end "one-stop" platform covering the entire pipeline—from early-stage R&D to full-scale commercial manufacturing. Powered by its proprietary SAVE (Synthetic Attenuated Virus Engineering) reverse genetics technology, the company has established a strong technical edge in the global animal health sector.
Notably, BioPOA’s flagship PoaVac PRRS Live Vaccine has secured regulatory approvals not only in South Korea, but also in Thailand, Cambodia, and Mexico, driving consistent revenue growth. The company is actively accelerating its global footprint, with regulatory review and approval processes currently underway in key Southeast Asian markets, including Vietnam and the Philippines.
"Our selection for the Innovation Premier 1000 is a testament to our R&D capabilities and market growth potential," said Sunhee Cho, CEO of BioPOA. "With this government backing, we will continue investing in strengthening our core competencies to boost our global competitiveness and accelerate our expansion into international markets."